FIGURE 2. Wild-type and mutant MYC show apoptotic, but not proliferative, differences in vivo.
From the following article:
Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants
Michael T. Hemann, Anka Bric, Julie Teruya-Feldstein, Andreas Herbst, Jonas A. Nilsson, Carlos Cordon-Cardo, John L. Cleveland, William P. Tansey and Scott W. Lowe
Nature 436, 807-811 (11 August 2005)
doi: 10.1038/nature03845
a, Flow cytometry showing BrdU incorporation in GFP-positive bone marrow cells 24 days after reconstitution. Data are representative of three independent experiments. b, Kaplan−Meier curve showing survival following adoptive transfer with HSCs co-infected with the indicated MYC-expressing retroviruses and a Bcl2-expressing retrovirus. c, In vivo GFP imaging showing disseminated lymphomas in mice 35 days after adoptive transfer with HSCs co-transduced with wild-type or mutant MYC and Bcl2. d, Representative histograms of DNA content of wild-type MYC/Bcl2 and mutant MYC/Bcl2 lymphomas.
